Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,489 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard Scheduling Clear all

Conditions: Breast Cancer
Interventions: Breast Cancer Screening Decision Aid; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 39 Years to 48 Years · Female only
Enrollment: 1,302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 9
States / cities: Philadelphia, Pennsylvania • Radnor, Pennsylvania

Conditions: Cesarean Section Complications
Interventions: Ibuprofen, acetaminophen, oxycodone; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Peripheral Artery Disease
Interventions: Fitbit Physical Activity Monitor, mHealth Glucometer, mHealth Blood Pressure; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sarcoma
Interventions: PET/MR; Diagnostic Test
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions: Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel; Drug · Procedure
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 78
States / cities: Irvine, California • Los Angeles, California • Orange, California + 64 more

Conditions: Carcinoma, Renal Cell
Interventions: Sunitinib; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Localized Prostate Cancer
Interventions: Aquablation Therapy, Active Surveillance; Device · Other
Lead sponsor: PROCEPT BioRobotics; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 27
States / cities: Chandler, Arizona • Los Angeles, California • Murrieta, California + 23 more

Conditions: Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Interventions: Enfortumab vedotin, Pembrolizumab; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions: Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Salem, Massachusetts

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Pembrolizumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoking, Cigarette, Smoking Cessation
Interventions: Varenicline, Combination nicotine patch and nicotine mini-lozenge treatment, Monetary incentives for initiating treatment, Automated tailored outreach, Care management, Wisconsin Tobacco Quit Line referral, Primary care provider referral, Untailored outreach, Multiple smoking cessation coaching calls; Drug · Behavioral · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Asthma in Children
Interventions: Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER), Enhanced Care (EC); Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 3 Years to 12 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Multiple Myeloma
Interventions: TAK-079, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Birmingham, Alabama • Monterey, California • Bethesda, Maryland + 6 more

Conditions: Diabetes Mellitus, Non Insulin Dependent Diabetes Mellitus
Interventions: Telehealth Bridge Visits, Standard of Care; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 20 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Postoperative Recovery, Total Knee Arthroplasty
Interventions: Xcelerated Recovery Nutritional Supplement; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 65 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cancer
Interventions: Augmented Whole-body Scanning via Magnifying PET, PET/CT; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Kidney Stones
Interventions: Ureteroscopy using the 6.3 Fr f-URS hugemed, Hugemed 6.3 Fr f-URS; Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Prostate Cancer, Prostate Cancer Metastatic
Interventions: 68Ga PSMA-11 injection, Positron Emission Tomography/Computed Tomography; Drug · Procedure
Lead sponsor: Dana Mathews; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Substance Use Disorders
Interventions: IntACT, Usual Care; Behavioral
Lead sponsor: Michael Incze; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
Interventions: Lurbinectedin; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 10 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 6
States / cities: Los Angeles, California • Iowa City, Iowa • Boston, Massachusetts + 3 more

Conditions: Arthropathy of Knee Joint, Arthropathy of Hip Joint
Interventions: personalized prehabilitation; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 55 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Barrett Esophagus, Esophageal Adenocarcinoma
Interventions: Sample Collection, Endoscopy results, Dietary questionnaire; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: New York, New York

Conditions: Healthcare Access for Taxi Drivers
Interventions: questionnaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 85 Years · Male only
Enrollment: 756 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Gastrointestinal Stromal Tumor (GIST)
Interventions: BGJ398, Imatinib Mesylate; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 4 more

Search by objective public record fields.

PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk

Towards Enhanced Recovery After Cesarean

Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)

PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing

WATER IV PCa (AS Sub-study)

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

Pembrolizumab for Advanced NSCLC and PS 2-3

Health Systems Reach Interventions Project

Telehealth-Enhanced Asthma Care for Home After the Emergency Room

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

ED Diabetes Screening and Outpatient Care - Aim 3

Nutrition and Swelling

Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection

Surgical Outcomes and Costs in Using the Shenzhen HugeMed 6.3 French Flexible Ureteroscope

The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer

Feasibility of an Interdisciplinary Intervention to Improve Care Transitions for Hospitalized Patients With Substance Use Disorders

Lurbinectedin in FET-Fused Tumors

A Personalized Prehabilitation Intervention In Elective Joint Replacement Surgery

The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)

Randomized Controlled Trial Examining Health Care Access Interventions for Taxi Drivers

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)